Article
The epigenetic function of androgen receptor in prostate cancer progression
21 Mar 2023
Abstract excerpt
Androgen and androgen deprivation (castration) therapies, including androgen receptor antagonists, are clinically used to treat patients with prostate cancer. However, most hormone-dependent prostate cancer patients progress into a malignant state with loss of hormone-dependency, known as castration (drug)-resistant prostate cancer (CRPC), after prolong androgen-based treatments. Even in the CRPC state with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
